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Soluble CD86 Is a Costimulatory Molecule
for Human T Lymphocytes
anergic (Harding et al., 1992; Gribben et al., 1995). More
recently, ICOS, a new member of the CD28 family, has
been described (Hutloff et al., 1999). The expression of
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ICOS on naive T cells is induced by activation (HutloffNathalie Herbault,* Liliane Goetsch,*
et al., 1999; Yoshinaga et al., 1999). ICOS interacts withAline Blaecke,* Pierre-Yves Dietrich,†
B7-RP1 (Yoshinaga et al., 1999), also described as B7hJean-Yves Bonnefoy,*‡ and Yves Delneste*
(Swallow et al., 1999), which is constitutively expressed*Centre d’Immunologie Pierre Fabre
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France molecule for human T cells, the ligand for which remains
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Hoˆpital Cantonal Universitaire de Gene`ve and ICOS, activated T cells may also transiently express
CH-1124 Gene`ve CTLA-4, a second ligand for CD80 and CD86 (Linsley et
Switzerland al., 1991b; Azuma et al., 1993). CTLA-4 engagement
can transduce an “off” signal, disengaging T cells from
further activation and proliferation (Walunas et al., 1994;
Krummel and Allison, 1995; Saito, 1998). However, onlySummary
CD28 is constitutively expressed by resting naive T cells,
suggesting that the CD28/B7 ligand pairs play an impor-CD86 is an important costimulatory molecule for the
tant role in the generation of an immune response. Inpriming and activation of naive and memory T cells,
agreement with this observation, CD28-deficient micerespectively. Here, we show that soluble CD86 is de-
(Shahinian et al., 1993) and transgenic mice producingtected in human serum. Soluble CD86 is produced by
a soluble CTLA-4-Fc molecule (Linsley et al., 1992) pre-resting monocytes and results from an alternatively
sent a reduced Th response.spliced transcript (CD86DTM) characterized by dele- CD80 and CD86 are type I membrane glycoproteins
tion of the transmembrane domain. Recombinant belonging to the immunoglobulin supergene family (Ba-
CD86DTM binds to CD28 and CTLA-4 and induces the jorath et al., 1994). In humans, their expression patterns
activation of T cells after stimulation with anti-CD3 differ according to the nature of the APC. CD86 expres-
mAb. CD86DTM also induces IFNg production by vi- sion is constitutive on monocytes (Azuma et al., 1993;
rus-specific CD81 memory human T cells stimulated Hathcock et al., 1994) and dendritic cells (Caux et al.,
with the Flu M1 peptide. The concentrations of soluble 1994; Yokozeki et al., 1996) and is upregulated by activa-
tion (Engel et al., 1994; McLellan et al., 1995). In contrast,CD86 found in human serum are sufficient to induce
CD80 is expressed at low levels on APC and upregulatedbiological activity. Soluble CD86 molecule, therefore,
following activation (Fleischer et al., 1996). CD80 andappears to be a functional costimulatory molecule
CD86 are also induced on T cells after activation (Haka-playing a potentially important role in immune surveil-
mada-Taguchi et al., 1998; Jeannin et al., 1999). Despitelance.
having the same ligands, CD80 and CD86 appear to be
involved in different mechanisms; CD80 can be moreIntroduction
potent than CD86 in inducing an anti-tumoral response
(Matulonis et al., 1996), while CD86 preferentially in-
Naive T cells require primary and costimulatory signals duces the production of a Th2 response (Freeman et
from antigen-presenting cells (APC) to be functionally al., 1995; Kuchroo et al., 1995). In CTLA-4-Ig transgenic
activated. The primary antigen-specific signal initiates mice, blocking the interaction of CD80/CD86 with their
activation with costimulatory signals inducing clonal ex- ligands results in defective T cell priming (Linsley et al.,
pansion and differentiation into effector cells (Lenschow 1992). Due to its constitutive expression on human APC,
et al., 1996; Chambers and Allison, 1997; Greenfield et CD86 has been suspected of being involved in the initia-
al., 1998). Costimulatory signals are provided by the tion of the immune response (Caux et al., 1994; Yi-qun
interaction of membrane molecules expressed by T cells et al., 1996; Manickasingham et al., 1998).
and APC. The biological activity of the costimulatory In this study, we report that soluble CD86 is detected
molecule CD28 has been extensively studied. CD28 is in human serum. Soluble CD86 is produced by resting
constitutively expressed by T cells and interacts with monocytes and results from an alternatively spliced
the B7 molecules CD80 (B7.1) (Yokochi et al., 1982; transcript characterized by the deletion of the trans-
Linsley et al., 1990) and CD86 (B7.2) (Azuma et al., 1993; membrane domain. Soluble CD86 provides a costimula-
Freeman et al. 1993). This interaction results in an in- tory signal to memory human T cells.
creased T cell proliferation, IL-2 production, and resis-
tance to apoptosis (Linsley et al., 1991a; Croft et al., Results
1992). T cells that bind antigen and do not receive a
costimulatory signal are thought to die or to become Detection of Soluble CD86 in Human Serum
and Identification of a CD86 mRNA
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Figure 1. PBMC Express an Alternatively
Spliced Variant of Human CD86 mRNA
(A) Identification of two CD86 transcripts in
human PBMC. RT-PCR was performed to
amplify the coding sequence of CD86 mRNA
in human PBMC. The membrane CD86 and
CD86DTM cDNA fragments were visualized
by ethidium bromide staining.
(B) Nucleotide sequence at the splice junction
of CD86 and CD86DTM. Nucleotide sequence
at the splice junction and the deduced amino
acid sequence of CD86DTM are shown.
(6.3 6 4.5 ng/ml, mean 6 SEM, ranging from 1 to 15 ng/ Fc protein (extracellular domain of CD86 or CD80 fused
to the CH2 and CH3 domains of mouse Fcg1) (Figure 3B).ml), 6/40 cancer patients (3.7 6 3.1 ng/ml, ranging from
1 to 10 ng/ml), and 8/40 subjects suffering from autoim- The preimmune rabbit serum did not recognize human
mune disease (4.6 6 2.1 ng/ml, ranging from 2 to 12 ng/
ml) (data not shown). Soluble CD86 can be produced
either by the shedding of the membrane form or through
an alternative mRNA splicing. RT-PCR analysis of CD86
mRNA revealed the constitutive expression of two tran-
scripts in resting human peripheral blood mononuclear
cells (PBMC) (Figure 1A). The largest form (972 bp) was
identical to the published CD86 sequence (Azuma et al.,
1993; Freeman et al., 1993; data not shown). The small-
est cDNA fragment (828 bp), named CD86DTM, has a
deletion from nucleotide (nt) 686 (starting from ATG co-
don) to nt 829 and encodes for a 275 amino acid poly-
peptide. According to the cd86 genomic organization
(Jellis et al., 1995), this cDNA is generated by alternative
splicing of the CD86 mRNA in which the exon 6 (encod-
ing for the transmembrane region) is deleted (Figure 1B).
The deletion does not affect the reading frame (Figure 1B).
Our results show that a soluble form of CD86 can
be detected in human serum and that human PBMC
express two CD86 mRNA variants.
Recombinant CD86DTM Is Expressed
as a Soluble Molecule
The deletion of exon 6 (encoding for the transmem-
brane domain) suggested that CD86DTM could be pro-
duced as a soluble molecule. Recombinant CD86 and
CD86DTM expressed in COS cells have an apparent
molecular weight of 65 and 48 kDa in nonreducing condi-
tions, respectively (Figure 2A). Membrane CD86 was
detected by FACS on the surface of COS cells trans-
fected with CD86 but not with CD86DTM cDNA (Figure
2B). A soluble molecule reactive with anti-CD86 mAbs
was detected by ELISA in the cell-free supernatant of
CD86DTM-transfected cells but not in the supernatants
of CD86-transfected cells and mock cells (Figure 2C).
These results show that recombinant CD86DTM is a
soluble molecule.
Figure 2. Recombinant CD86DTM Is Produced as a Soluble Mol-Soluble CD86 Detected in Human Serum Is
eculeEncoded by the CD86DTM Transcript
COS cells were transiently transfected with the pCDNA3.1 vectorIn order to selectively detect CD86DTM, a specific poly-
containing CD86 or CD86DTM cDNA. After 48 hr, protein extractsclonal serum was produced by immunizing rabbits with
were size separated by nonreducing SDS-PAGE, and CD86 expres-the peptide DEAQRVFKSSKTSSCDKSD, located within
sion was analyzed by Western blotting (A). Membrane CD86 expres-
the intracellular domain of CD86. Western blotting analy- sion was analyzed by FACS (B), and soluble CD86 was determined
sis showed that the serum recognized both membrane by ELISA in the concentrated culture supernatants (C). The concen-
CD86 and CD86DTM molecules produced in COS cells tration of soluble CD86 was determined using purified recombinant
(Figure 3A). In ELISA, the polyclonal antibody recognized CD86DTM as a standard. Results are expressed in nanograms/milli-
liter (mean 6 SD, n 5 5).recombinant CD86DTM but not the CD86-Fc and CD80-
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Figure 3. Soluble CD86 Detected in Human
Serum Is Identical to CD86DTM
(A and B) Characterization of the anti-
CD86DTM–specific polyclonal Ab. (A) West-
ern blot analysis shows that the anti-
CD86DTM polyclonal Ab recognizes both re-
combinant CD86DTM and membrane CD86
expressed by COS-transfected cells. (B) The
anti-CD86DTM polyclonal Ab recognizes re-
combinant CD86DTM but not CD86-Fc and
CD80-Fc–fusion proteins by ELISA. Results
are expressed in optical density values.
(C) Soluble CD86DTM is detected in human
serum. Serum containing the highest levels
of soluble CD86 (n 5 17) (closed circle) as
determined by ELISA using the anti-CD86
mAb and negative serum (n 5 20) (open circle) were tested by ELISA using the anti-CD86DTM polyclonal Ab. The concentration of soluble
CD86 was determined using purified recombinant CD86DTM. Results are expressed in nanograms per milliliter.
serum and recombinant CD86DTM and CD86-Fc (data (Figure 5B) or CTLA-4-transfected cells (MFI 5 49 6 6)
(Figure 5D) but not to mock-transfected cells (Figuresnot shown). The CD86DTM-specific polyclonal antibody
5B and 5D). This binding is inhibited by 10 mg/ml anti-detected soluble CD86 in 17/24 CD861 serums, whereas
CD86 mAb (83% 6 10% and 94% 6 8% inhibition onno signal was observed in 20/20 CD862 serums tested
CD28 and CTLA-4 transfected cells, respectively;(Figure 3C). The levels detected in the different serums
mean 6 SD, n 5 4) (Figure 5B) and by 5 mg/ml CTLA-with the ELISA for soluble CD86 or specific for CD86DTM
4-Fc (68% 6 8% and 75% 6 6% inhibition, respectively)were identical. However, due to a lower sensitivity of
(data not shown) but not by an anti-CD80 mAb (data notthe ELISA, levels of soluble CD86 lower than 5 ng/ml
shown). Recombinant CD86DTM (10 mg/ml) also binds towere not detected in this assay.
the human T lymphoma cell line Jurkat (MFI 5 38 6 8,Taken together, these results show that the soluble
mean 6 SD, n 5 3) (data not shown), which constitutivelyform of CD86 detected in human serum can be gener-
expresses CD28. This binding is also inhibited by anated by translation of the CD86DTM mRNA.
anti-CD86 mAb (70% 6 12% inhibition) and CTLA-4-Fc
(68% 6 8% inhibition) but not by an anti-CD80 mAb.Resting Monocytes Constitutively Express CD86DTM
We next evaluated the biological activity of recombinantmRNA and Produce Soluble CD86
soluble CD86DTM. In vitro assays showed thatThe expression of CD86 versus CD86DTM mRNA was
CD86DTM increased the proliferation of T cells stimu-evaluated in different cell types by RT-PCR. Results
lated with a suboptimal concentration of an anti-CD3show that the two splice variants are constitutively ex-
mAb. This effect was significant at 10 ng/ml (stimulationpressed by nonstimulated monocytes (Figure 4A), while
index [SI] 5 8.4 6 1.3; mean 6 SD, n 5 6; p , 0.05) andonly CD86 mRNA was expressed by peripheral blood
maximal at the highest concentration tested (1 mg/ml)and tonsillar B cells, in vitro–generated dendritic cells,
(SI 5 25 6 4; p , 1024) compared to stimulation withalveolar macrophages (Figure 4A), and different trans-
the anti-CD3 mAb alone (SI 5 2.5 6 0.6) (Figure 6A). Tformed cell lines expressing membrane CD86 (data not
cell proliferation was inhibited by 10 mg/ml neutralizingshown). None of the CD86 transcripts were detected in
anti-CD86 mAb (80% 6 6% inhibition) or 5 mg/ml CTLA-T cells, NK cells, neutrophils, lung epithelial cells, or
4-Fc (82% 6 9% inhibition) but not by anti-CD80 andmicrovascular endothelial cells (data not shown). Activa- the isotype control mAbs (Figure 6B). No proliferation
tion of monocytes with 100 ng/ml LPS, 10 U/ml IFNg, was induced by soluble CD86DTM in the absence of the
or 1 mg/ml anti-CD40 mAb resulted in the preferential anti-CD3 mAb. As a control, anti-CD3 plus anti-CD28
expression of membrane CD86 mRNA (Figure 4B). Using mAb induced a stronger T cell proliferation (SI 5 74 6
either mAbs (data not shown) or the CD86DTM-specific 11; mean 6 SD, n 5 5) (Figures 6A and 6B). T cell
serum (Figure 3C), results showed that monocytes spon- proliferation was associated with cytokine production.
taneously released soluble CD86. As expected, no solu- CD86DTM, used at the optimal concentration of 100 ng/
ble CD86 was observed in B cell, dendritic cell, or alveo- ml, induced a higher production of IFNg (12 6 2.5 ng/
lar macrophage culture supernatants. Soluble CD86 ml; mean 6 SD, n 5 6) (Figure 6C) and IL-2 (5.6 6 0.9
production was abolished in monocytes by activation ng/ml ) (Figure 6D) by anti-CD3 mAb-stimulated T cells
with LPS, anti-CD40 mAb, or IFNg (Figure 4C). compared with a stimulation with the anti-CD3 mAb
These data demonstrate that nonstimulated human alone (4 6 0.8 ng/ml and 1.9 6 0.2 ng/ml , respectively)
monocytes produce soluble CD86DTM and that activa- (Figures 6C and 6D). Both IFNg and IL-2 production
tion inhibits this production. was inhibited by 10 mg/ml neutralizing anti-CD86 mAb
(66% 6 10% and 52% 6 8% inhibition, respectively) or 5
CD86DTM Is a Costimulatory Molecule mg/ml CTLA-4-Fc (72% 6 13% and 61% 6 9% inhibition,
We further analyzed the biological activity of soluble respectively) (Figures 6C and 6D) but not by anti-CD80
CD86. In a first set of experiments, we evaluated whether or isotype-matched mAbs (data not shown). As a con-
the molecule CD86DTM can bind to its ligands, CD28 trol, IFNg and IL-2 production by T cells activated with
and CTLA-4. The expression of CD28 and CTLA-4 by anti-CD3 plus anti-CD28 mAb was 25 6 4.5 and 6.8 6
COS cells was analyzed by FACS (Figures 5A and 5C). 1.1 ng/ml, respectively (Figures 6C and 6D). Lymphokine
Results show that 10 mg/ml recombinant CD86DTM production was undetectable when soluble CD86DTM
was used alone (data not shown). Previous studies havebinds to CD28-transfected cells (MFI 5 72 6 8, n 5 3)
Immunity
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Figure 5. CD86DTM Binds to CD28 and CTLA-4
The binding of CD86DTM to its ligands CD28 and CTLA-4 was evalu-
ated by FACS using CD282 (A) and CTLA-4–transfected COS cells
(C). The binding of c-myc–tagged CD86DTM on transfected cells (B
and D) was evaluated using an anti-c-myc mAb (clone 9E10) re-
vealed with an FITC-labeled anti-mouse Ig Ab. In some experiments,
CD86DTM was incubated with neutralizing anti-CD86 mAb before
the binding assay.
These results show that as previously reported for mem-
brane CD86 (Linsley et al., 1991a; Azuma et al., 1993;
Freeman et al., 1993), CD86DTM in association with anti-
CD3 mAb potentiates proliferation and lymphokine pro-
duction by T cells. CD86DTM acts, at least in part, by
inducing the phosphorylation of Vav.
CD86DTM Costimulates Memory T Lymphocytes
Naive T cells require a strong costimulatory signal to beFigure 4. CD86DTM Expression Is Restricted to Human Monocytes
efficiently activated, while memory T cells require lowand Regulated by Activation
stringency activation signals (Croft et al., 1992; Liu and(A) CD86DTM mRNA is selectively expressed in monocytes. The
Janeway, 1992; Yi-qun et al., 1996; Manickasingham et al.,expression of the CD86DTM trancript was analyzed by RT-PCR in
1998). We have thus evaluated whether soluble CD86DTMfreshly isolated monocytes, peripheral blood, tonsillar B cells, in
vitro–generated dendritic cells, and alveolar macrophages. The am- can provide a similar activation signal to naive and mem-
plified fragments were size separated on a 1% agarose gel and ory T lymphocytes. Cell cycle analysis revealed that
visualized by ethidium bromide staining. 16% 6 1.6% (mean 6 SD, n 5 3) of CD45RO1 proliferate
(B) Regulation of CD86DTM mRNA expression in human monocytes. in response to CD86DTM plus anti-CD3 mAb, while only
Human monocytes were either nonstimulated or stimulated with 11.2% 6 1.2% (p , 0.05) proliferate in response to anti-
LPS, anti-CD40 mAb, or IFNg. The CD86DTM transcript expression
CD3 mAb alone (Figure 7A). Naive T cells also proliferatewas analyzed after a 6 hr stimulation. RNA integrity and cDNA syn-
in response to CD86DTM plus anti-CD3 mAb when com-thesis was verified by amplifying GAPDH cDNA.
pared to a stimulation with anti-CD3 mAb alone (6.5% 6(C) Nonactivated human monocytes produce soluble CD86DTM.
0.6% compared to 4.7% 6 0.9%, respectively) (FigureHuman monocytes were nonstimulated or stimulated with LPS, anti-
CD40 mAb, or IFNg. After an overnight incubation, soluble CD86 7A). We have thus evaluated whether soluble CD86 pro-
was detected by ELISA using the specific CD86DTM polyclonal vides the costimulatory signal required to activate anti-
serum as detection Ab. The concentration of soluble CD86 was gen-specific memory cells. The influenza-specific mem-
determined using purified recombinant CD86DTM. Results are ex- ory CD81 T cells circulate in a state whereby they can
pressed in nanograms per milliliter. rapidly display effector function following stimulation
(Bednarek et al., 1991; Lalvani et al., 1997). T cells from
HLA-A2 subjects were stimulated for 6 hr with the influ-reported that Vav is phosphorylated in response to CD28
ligation (Klasen et al., 1998). We thus evaluated whether enza nonapeptide GILGFVFTL (Bednarek et al., 1991)
plus CD86DTM, and intracytoplasmic IFNg productionCD86DTM could also induce the phosphorylation of this
protein. Immunoprecipitation and Western blotting anal- was detected among CD81 T cells. Representative data
obtained from one of five subjects are presented.ysis showed that like the anti-CD28 mAb, cross-linked
CD86DTM could induce the phosphorylation of Vav in CD86DTM induced an increase of IFNg production in
CD45RO1 T cells compared with CD45RA1 T cellsJurkat cells (Figure 6E).
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Figure 6. CD86DTM Is a Costimulatory Mole-
cule for Human T Cells
(A and B) T cell proliferation was determined
after 72 hr stimulation by [3H]thymidine incor-
poration. Results are expressed in counts per
minute, mean 6 SD. (A) CD86DTM potenti-
ates the proliferation of anti-CD3 mAb–acti-
vated T cells. Human T cells were stimulated
with a suboptimal concentration of anti-CD3
mAb without or with recombinant CD86DTM.
Positive control of T cell proliferation was in-
duced by anti-CD3 plus anti-CD28 mAbs. (B)
CD86DTM-induced T cell proliferation is in-
hibited by blocking CD86. Human T cells were
stimulated with a suboptimal concentration
of anti-CD3 mAb plus CD86DTM without or
with CTLA-4-Fc, anti-CD86, anti-CD80, or
isotype control mAbs.
(C and D) CD86DTM potentiates the produc-
tion of IFNg and IL-2 by anti-CD3 mAb–
activated T cells. T cells were stimulated with
anti-CD3 mAb without or with recombinant
CD86DTM. In some experiments, neutralizing
anti-CD86 mAb or CTLA-4-Ig were added.
IFNg and IL-2 production was determined by
FACS analysis as mentioned in the Experi-
mental Procedures section. A stimulation
with anti-CD3 plus anti-CD28 mAbs was per-
formed as a control. Results are expressed
in nanograms per milliliter.
(E) CD86DTM induces tyrosine phosphoryla-
tion of Vav. Jurkat T cells were nonstimulated
(1) or stimulated with cross-linked CD86DTM
(2), an anti-CD28 mAb (3), or with an anti-c-
myc plus goat anti-Ig antibody (4) for 5 min at
378C. After immunoprecipitation, the tyrosine
phosphorylation of Vav was analyzed by im-
munoblotting using anti-phosphotyrosine mAb
(a-PY, upper panel). The levels of Vav expres-
sion were determined by immunoblotting us-
ing an anti-Vav Ab (lower panel).
(0.66% and 0.03%, respectively) or nonstimulated cells previously reported. A spliced variant of the CD80
mRNA, characterized by the deletion of exon 3 and re-(0.05% and 0.02%, respectively) (Figure 7B). Similar
results were obtained by activating T cells with the pep- sulting in the loss of the C-like domain, has been found
in lymphoid organs (Inobe et al., 1994, 1996; Guo et al.,tide plus anti-CD28 mAb (1.4% and 0.06% among
CD81CD45RO1 and CD81CD45RA1 cells produce IFNg, 1995). Exons 1 and 5 of murine CD86 can be used in
alternative fashion to generate four transcripts (differingrespectively) (Figure 7B). In contrast, the frequency of
IFNg-producing cells was not modified when cells were in their 59 untranslated and signal regions) that encode
the same molecule (Borriello et al., 1995). An additionalstimulated with CD86DTM alone (Figure 7B).
These results show that CD86DTM costimulates anti- alternatively spliced variant of murine CD86 encoding a
partial IgV-like domain has also been reported (Borriellogen-specific memory T cells.
et al., 1995). The expression of these spliced transcripts
is controlled by activation, as observed here with humanDiscussion
CD86. However, no spliced variant generating soluble
CD86 has been described in mice, hindering the evalua-We report here the detection of soluble CD86 in human
tion of biological activity of soluble CD86 in in vivoserum. Soluble CD86 is generated from an alternative
mouse models. Thus, to our knowledge, these data aresplicing of the CD86 mRNA (CD86DTM), which results
the demonstration of a naturally occurring alternativein the deletion of the transmembrane domain. CD86DTM
splicing of the CD86 mRNA, resulting in the synthesisis expressed by nonactivated monocytes. Soluble re-
of a soluble costimulatory molecule. The Ig-like structurecombinant CD86DTM potentiates proliferation and lym-
of CD86 is maintained by two intrachain disulfide bondsphokine production by human T cells stimulated with
between Cys40–Cys110 (V-type domain) and Cys157–Cys218anti-CD3 mAb or a recall antigen.
(C-type domain) (Azuma et al., 1993; Freeman et al.,The human cd86 gene is a single-copy gene organized
1993; Bajorath et al., 1994) with ligand binding involvinginto eight exons (Jellis et al., 1995). The transcript
at least the V-type domain (Rennert et al., 1997). TheCD86DTM is generated by the splicing of exon 6, which
reading frame of the CD86DTM mRNA is not affected.results in the deletion of the transmembrane domain.
Moreover, recombinant CD86DTM binds to CD28 andThe acceptor and donor sites conform with the consen-
CTLA-4 and costimulates T cells in a CD28-depen-sus splice-junction sequences (Mount, 1982). Alterna-
tively spliced variants of murine B7 molecules have been dent manner, demonstrating that the binding sites of
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ligand. These results are in agreement with the observa-
tion that anti-CD28 mAb (Linsley et al., 1991a) and di-
meric CD86DTM transduce a more potent costimulatory
signal than monomeric CD86DTM. The lower amplitude
of T cell activation induced by monomeric CD86DTM
could result either from a lower avidity between soluble
CD86 and its ligand or a higher dissociation rate com-
pared with membrane CD86, which could be responsible
for the generation of a lower costimulatory signal. In
contrast with monomeric CD86DTM, the cross-linking
of the fusion protein CD86-Ig was required to potentiate
the anti-CD3 mAb–stimulated T cell proliferation (Ren-
nert et al., 1997). One can speculate that the monomeric
structure of soluble CD86DTM is sufficient to activate T
cells or that soluble CD86 can exist in a noncovalent
oligomeric form. A recent study showing that soluble
CD80 can form homodimers in solution (Ikemizu et al.,
2000) is in favor of this hypothesis. Interestingly, cross-
linked CD86DTM induced the phosphorylation of the
CD28 signal-transducing molecule Vav (Klasen et al.,
1998). Although we cannot exclude the possibility that
CD86DTM may also interact with CTLA-4 and thus gen-
erate an inhibitory signal, these data demonstrate that
soluble CD86 acts, at least in part, by inducing a CD28-
dependent activation signal.
Membrane CD86, which is constitutively expressed
by monocytes, B cells, and dendritic cells (Caux et al.,
1994; Engel et al., 1994; Vyth-Dreese et al., 1995; Yoko-
zeki et al., 1996), has been shown to play an important
role in the priming of naive T cells and activation of
memory T cells (Yi-qun et al., 1996; Manickasingham et
Figure 7. CD86DTM Is a Costimulatory Molecule for Human Memory al., 1998). Since the activation of naive T cells requires
T Cells
strong activation signals that are provided by profes-
(A) CD86DTM induces the proliferation of CD45RO1 T cells. After sional APC (Liu and Janeway, 1992), and the activation
stimulation with an anti-CD3 mAb, without or with CD86DTM, the
of recently activated memory T cells can be elicited withphenotype of proliferating T cells was measured by Hoechst 33342
anti-CD3 mAb alone (Van de Velde et al., 1993), moststaining and labeling with anti-CD45RA and anti-CD45RO mAbs. T
memory T cells are still dependent on CD28 triggeringcell activation with anti-CD3 plus anti-CD28 mAb was performed as
for their activation (Yi-qun et al., 1996). FACS analysisa control. Results are expressed as a percentage of cells in S1G2M
phases of the cell cycle among naive and memory subpopulations, revealed that soluble CD86DTM potentiated the prolifer-
mean 6 SD. ation of memory and naive T cells.
(B) CD86DTM induces IFNg production by CD81 T cells stimulated We have also observed that CD86DTM potentiates
with the influenza M1 peptide. PBMC from HLA-A2 donors were the activation of memory T cells stimulated with a recall
incubated with the flu M1 nonapeptide with or without CD86DTM. antigen: recombinant CD86DTM increased the fre-
As a control, cells were incubated with the peptide plus an anti- quency of IFNg-producing influenza-specific memory T
CD28 mAb. The frequency of IFNg-producing CD81 cells among the
cells stimulated with the flu M1 peptide. These resultsCD45RA1 and CD45RO1 T lymphocytes was determined by FACS.
are in agreement with the fact that memory T lympho-Representative results obtained with one subject are presented.
cytes are less dependent than naive T cells on the ampli-
tude of the costimulatory signal to be efficiently acti-
CD86DTM are conserved. These data are also in agree- vated (reviewed by Croft, 1994). These data suggest that
ment with the observation that the V-like domain of B7 soluble CD86 could be involved (1) in the activation of
molecules is sufficient to activate T cells (Rennert et al., memory T cells and/or (2) in maintaining the “activation”
1997). status of CD45RO1 T lymphocytes (Zinkernagel et al.,
As previously reported for membrane CD86 (Linsley 1996). A similar role for membrane CD86 in the regulation
et al., 1991a), recombinant soluble CD86DTM potenti- of a memory antigen–specific restimulation has been
ates the proliferation and lymphokine production by previously reported (Keane-Myers et al., 1997). More-
anti-CD3 mAb–stimulated T cells. Interestingly, dimeric over, the expression of CD86DTM mRNA and production
soluble CD86DTM (produced as a GST fusion protein) of soluble CD86 are restricted to nonactivated human
was equally potent as anti-CD28 mAb in increasing the monocytes, suggesting that soluble CD86 could be in-
proliferation of anti-CD3 mAb–stimulated T cells (data volved in the early phase of the immune response, when
not shown). The covalent homodimeric molecules CD28 activation of memory T cells may occur. These results
and CTLA-4 have two binding sites (2:2 stochiometry) are in favor of a role for soluble CD86 in the immune
(Linsley et al., 1995), and the oligomerization or cluster- surveillance. In contrast, the initiation of a specific im-
ing of membrane CD80/CD86 has been proposed in mune response requires the exclusive expression of
order to explain the higher avidity of CTLA-4-Ig to mem- membrane CD86, which provides a potent costimulatory
brane CD86 compared to monomeric CD86 (Symington signal to naive T cells.
et al., 1993). This higher avidity should enhance the signal- In agreement with an important immunoregulatory
role played by soluble CD86, an immunoreactive forming by increasing the time of receptor occupancy by the
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Cloning and Sequencing of CD86 mRNA Variantsof CD86 was detected in human serum. The existence
Total RNA was extracted with the Trizol reagent (Life Technologies),of a biologically active form of soluble CD86 has been
and poly(A)1 RNA was purified using oligo-dT-coated magneticpreviously suspected. Porcine endothelial cells consti-
beads (Dynal) according to the manufacturer’s recommendations.tutively release a soluble factor that mediates a CD28-
Single-strand cDNA was synthesized using 1 mg of poly(A)1 RNA
dependent T cell proliferation (Davis et al., 1996). How- by reverse transcription using an oligo-dT primer (Amersham Phar-
ever, we did not detect an alternatively spliced variant of macia Biotech). Total RNA from human alveolar macrophages, lung
CD86 in human endothelial cells, suggesting that soluble epithelial cells, and microvascular endothelial cells were kindly
CD86 found in human serum could be predominantly provided by Dr. P. Gosset (Institut Pasteur de Lille, Lille, France).
PCR reactions were performed with cDNA corresponding to 10 ngproduced by monocytes. Interestingly, the concentra-
poly(A)1 RNA. CD86 mRNA was amplified with primers designed totion range of soluble CD86 found in human serum is
amplify the entire coding sequence of CD86 (59-ATGGGACTGAGTAsimilar to that which induces in vitro biological activity.
ACATTCTCTTTGTGATGGCCT-39 and 59-CTCGAGTTAAAAACATGTWe cannot exclude the possibility that in some condi-
ATCACTTTTGTCGCATGA-39). The PCR reaction was performed astions, soluble CD86 could also be generated by shed-
follows: 948C for 4 min, then 25 cycles 948C for 30 min, 608C for 30
ding of the membrane form. Collectively, our results min, and 728C for 1 min followed by a final extension at 728C for 5
show that serum-soluble CD86, generated by alternative min. The amplified fragments were size separated on a 1% agarose
splicing, is likely to be produced by circulating mono- gel and visualized by ethidium bromide. After excision from the gel,
cytes, which represent a large fraction of the PBMC. each amplified cDNA fragment was subcloned into a TA cloning
vector (pCRII; InVitrogen, Leek, The Netherlands). Sequencing wasThis soluble costimulatory molecule can thus play an
performed using the ABI-PRISM Dye Terminator Cycle Ready Reac-important role in the immune surveillance against recall
tion kit (Perkin Elmer, Foster City, CA). Two cDNAs of different sizeantigens and acts as a constant activation stimulus in-
were amplified and called CD86 and CD86DTM (see the Resultsvolved in the regulation of memory human T cell homeo-
section). The expression of CD86 mRNA in activated versus non-stasis.
stimulated human monocytes was evaluated by PCR using the
above mentioned primers. RNA integrity and cDNA synthesis was
verified by amplifying GAPDH cDNA (59-TCCACCACCCTGTTGCTExperimental Procedures
GTA-39 and 59-ACCACAGTCCATGCCATCAC-39).
Detection of Soluble CD86
CD86 and CD86DTM Transfected COS CellsSoluble CD86 was evaluated by ELISA using commercial mAbs in
The CD86 and CD86DTM cDNAs were subcloned in the vectorthe culture supernatants or serum of healthy subjects (n 5 60) and
pCDNA3.1 and pCDNA3.1-A Myc-His (InVitrogen) and used tosubjects suffering from cancer (n 5 40) and autoimmune disease
transfect COS cells. COS cells (ATCC, Manassas, VA) were cultured(n 5 40). In order to verify that soluble CD86 is identical to CD86DTM
in DMEM medium supplemented with 10% FCS, L-glutamine, andand not generated by shedding of the membrane form, a specific
antibiotics (all from Life Technologies) and transfected by lipofectionCD86DTM polyclonal antibody was generated by immunization of
(Fugene; Boehringer Mannheim, Mannheim, Germany). Expressiona rabbit with the peptide DEAQRVFKSSKTSSCDKSDT, whose se-
of membrane recombinant molecules was evaluated by FACS analy-quence is localized in the intracytoplasmic tail of CD86. This domain
sis using FITC-labeled anti-CD86 mAb (PharMingen, San Diego,is conserved in soluble CD86DTM. After incubation with the human
CA). The production of soluble recombinant CD86 was assessedserum, plates were incubated with the rabbit serum diluted at
by ELISA in the cell-free supernatants. Briefly, the anti-CD86 mAb1:5000, and bound Abs were detected using a peroxidase-labeled
(clone IT2.2) (PharMingen) was coated (1 ng/100 ml/well) in 96-wellanti-rabbit Ig Ab (Pierce, Rockford, IL) revealed with the substrate
plates (Life Technologies) in 0.1 M phosphate buffer (pH 4.0) (16 hro-phenylene diamine. Results are expressed in optical density val-
at 48C) before incubation for 2 hr at room temperature with PBS/ues after subtraction of the value obtained with in the preimmune
BSA 1%. After washing, plates were incubated for 16 hr at 48C withrabbit serum.
culture supernatant (200 ml/well). Bound CD86 was detected with
a biotin-labeled anti-CD86 mAb (clone FUN-1) (PharMingen) fol-
lowed by incubation with streptavidin-biotinylated HRP (used atIsolation and Activation of Human Cells
1/5000; Amersham Pharmacia Biotech) and revealed by the sub-Human PBMC were isolated by centrifugation on Ficoll/Paque
strate o-phenylene diamine (Sigma). CD86 expression in transfected(Amersham Pharmacia Biotech, Uppsala, Sweden). T cells were puri-
COS cells was also evaluated by Western blotting. Cells werefied by rosetting with sheep red blood cells; the purity, determined
washed in ice-cold PBS before lysis in 10 mM phosphate buffer (pHby flow cytometry on a FACScan cytofluorometer (Becton Dickinson,
7.4) containing 1% Nonidet P40 (Sigma) and protease inhibitorsSan Jose, CA) using an FITC-labeled anti-CD3 mAb (Becton Dickin-
(Boehringer Mannheim). Proteins from 5 3 106 cells were electropho-son), was .95%. Human peripheral blood B cells were purifed by
retically separated on a 10% polyacrylamide gel in reducing condi-flow cytometry using an FITC-labeled anti-CD19 mAb (Becton Dick-
tions and then transferred onto a nitrocellulose membrane (Biorad,inson). Tonsillar B cells were isolated from Ficoll-separated tonsillar
Ivry sur Seine, France). After saturation, membranes were incubatedmononuclear cells by a two-step negative-selection procedure us-
with an anti-CD86 mAb (R&D Systems). After washing, membranesing sheep erythrocyte rosetting and magnetic bead depletion (Dynal,
were incubated with peroxydase-labeled anti-mouse IgG Ab (Amer-Oslo, Denmark) to remove T cells, as previously reported (Jeannin
sham Pharmacia Biotech), and bound antibodies were detectedet al., 1995). B cell purity was routinely .98% as determined by
using the ECL system (Amersham Pharmacia Biotech).FACS analysis using an FITC-labeled anti-CD20 mAb (Becton Dick-
inson). Monocytes were either purified by FACS on the basis of
FSC/SSC parameters or using immunomagnetic beads coated with Production and Purification of Recombinant CD86DTM
an anti-CD14 mAb (MACS; Miltenyi, Bergish Gladbach, Germany); The recombinant CD86DTM molecule was produced in Sf9 cells.
purity was .98%. Dendritic cells were generated in vitro by activat- The CD86DTM cDNA was inserted in the pAcSecG2T baculovirus
ing monocytes for 7 days with IL-4 plus GM-CSF (R&D Systems, transfer vector (PharMingen) into which was introduced an enzy-
Abingdon, UK); purity was .98% as assessed by CD1a expression matic cleavage site for the protease 3C (Walker et al., 1994) between
and absence of CD83 labeling (Immunotech, Marseille, France). In the CD86DTM and GST fragments. Viral particles were prepared as
some experiments, monocytes were cultured in complete medium recommended by the manufacturer. Sf9 insect cells were grown at
(RPMI 1640 medium supplemented with 5% FCS and antibiotics 278C in TNM-FH medium (Life Technologies). Recombinant baculo-
reagent) (all from Life Technologies, Cergy Pontoise, France) and virus was generated in vivo in Sf9 cells using Baculogold viral DNA
were either unstimulated or stimulated with 10 ng/ml LPS (Sigma, (PharMingen). Sf9 cells were infected at a multiplicity of infection
St Louis, MO), 10 U/ml IFNg (R&D Systems), or 1 mg/ml anti-CD40 of 0.5. After 12 hr, the culture medium was changed to serum-free
Sf-900-II medium (Life Technologies). The cell culture supernatantsmAb (Ancell, Bayport, MN).
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were harvested at 72 hr and analyzed by ELISA for the presence of and electrotransferred on nitrocellulose membranes. For immu-
noblotting, membranes were probed with a Vav-specific antibodyrecombinant CD86DTM. Cells and cellular debris were sedimented
by centrifugation. The supernatants were 20-fold concentrated and or an anti-phosphotyrosine mAb (clone 4G10; UBI, Lake Placid, NY).
After washing, membranes were incubated with peroxidase-labeledthe CD86DTM molecule was purified on a GSH-Sepharose column
(Amersham Pharmacia Biotech). After an overnight incubation at anti-mouse or -rabbit antibodies, and bound antibodies were de-
tected using ECL (Amersham Pharmacia Biotech).48C under agitation, the column was washed and resuspended with
PreScission cleavage buffer before addition of GST-PreScission
(Amersham Pharmacia Biotech). After a 4 hr incubation at 48C under Activation of Influenza-Specific CD81 T Cells
agitation, the unbound fraction was collected and dialyzed against The frequency of activated influenza M protein-specific T cells was
PBS. Protein purity was assessed by Coomassie blue staining and evaluated as previously reported (Lalvani et al., 1997). Briefly, PBMC
Western blotting. at 1 3 106 cells/ml in 200 ml complete medium were cultured for 6
hr and stimulated with 10 mg/ml HLA-A2-restricted influenza peptide
FluM158–66 (GILGFVFTL), in the presence of recombinant CD86TM orBinding Experiments
3 mg/ml anti-CD28 mAb (Becton Dickinson). Brefeldin A (Sigma), anThe binding of recombinant CD86DTM to CD28 was measured by
inhibitor of intracellular transport that prevents secretion of synthe-FACS. COS cells were transfected with pCDNA3.1 containing CD28
sized cytokines, was added in the last 4 hr. Cells were then washedor CTLA-4 cDNA. Expression of membrane CD28 and CTLA-4 on
once in cold PBS and then resuspended in 2 ml PBS containing 1transfected cells was verified by FACS analysis using FITC-labeled
mM EDTA. After 10 min incubation at 378C, cells were washed andanti-CD28 and anti-CTLA-4 mAbs (PharMingen). Transfected cells
resuspended in 200 ml PBS/1% BSA/0.01% NaN3. Cells were thenwere incubated with 10 mg/ml c-myc-tagged recombinant CD86DTM.
incubated for 30 min at 48C with an allophycocyanin (APC)-labeledBound CD86DTM was detected with a biotin-labeled anti-c-myc mAb
anti-CD8 mAb (Caltag, Burlingame, CA) and either phycoerythrin-revealed by FITC-labeled streptavidin (PharMingen). In some experi-
labeled anti-CD45RA or -CD45R0 mAb (Dako). After washing, cellsments, a neutralizing anti-CD86 mAb (PharMingen) or CTLA-4-Ig
were fixed in 4% paraformaldehyde in PBS for 10 min at 48C and(Ancell) were added. Results are expressed as mean of fluorescence
permeabilized by a 15 min incubation at 48C in PBS/1mM HEPES/intensity (MFI) values.
0.1% saponin in the presence of 5 mg/ml FITC-labeled anti-human
IFNg mAb or FITC-labeled isotype control mAb (both from Phar-T Cell Activation Assays
Mingen, San Diego, CA). After two washes in PBS/1mM HEPES/T cell activation induced by recombinant CD86DTM was measured
0.01% saponin, cells were analyzed on a FACSvantage (Bectonby [3H]thymidine incorporation and IFNg and IL-2 production. Human
Dickinson). For each sample, 30,000 events were acquired afterPBMC (2.5 3 105 cells/ml), cultured in 96-well culture plates (Life
gating on CD81 cells.Technologies) (200 ml/well), were either nonstimulated or stimulated
with 100 pg/ml anti-CD3 mAb, 30 pg/ml anti-CD3 plus 10 ng/ml
Acknowledgmentsanti-CD28 mAbs, or 100 pg/ml anti-CD3 mAb plus 1–1000 ng/ml
recombinant CD86DTM. In some experiments, 10 mg/ml of the neu-
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help of Alexandra Gonzales and Fabienne Damien. We are gratefulhr. Radioactive incorporation was measured by standard liquid-
to Dr. Philippe Gosset (Unite´ INSERM U416, Institut Pasteur, Lille,scintillation counting. Results are given in counts per minute (cpm),
France) for providing RNA from different human cells.in stimulation index (SI) calculated as follows: A/O, where A and O
are the cpm values obtained when cells were stimulated or not,
Received February 23, 2000; revised July 27, 2000.respectively, or as a percent of decrease, (A-O/A) 3 100, where A
and O are the values obtained in the absence or presence of a
neutralizing anti-CD86 mAb, respectively. In other experiments, the References
frequency of naive versus memory proliferating T cells was mea-
sured using an FITC-labeled anti-CD45RA or anti-CD45RO mAbs Azuma, M., Ito, D., Yagita, H., Okumura, K., Philipps, J.H., Lanier,
(Dako, Glostrup, Denmark) after labeling with Hoechst 33342 (Molec- L.L., and Somoza, C. (1993). B70 antigen is a second ligand for
ular Probes, Eugene, OR). To measure lymphokine production, CTLA-4 and CD28. Nature 366, 76–79.
PBMC were cultured in 24-well plates (Life Technologies) at 2 3 106 Bajorath, J., Peach, R.J., and Linsley, P.S. (1994). Immunoglobulin
cells/ml, 2 ml/well and stimulated with 100 pg/ml anti-CD3 mAb, 30 fold characteristics of B7–1 (CD80) and B7–2 (CD86). Protein Sci.
pg/ml anti-CD3 plus 10 ng/ml anti-CD28 mAbs, or 30 pg/ml anti- 3, 2148–2150.
CD3 mAb plus 100 ng/ml recombinant CD86DTM. IFNg production
Bednarek, M.A., Sauma, S.Y., Gammon, M.C., Porter, G., Tam-was measured 24 hr later using Quantiflow Immunoassay kits (BioE,
hankar, S., Williamson, A.R., and Zweerink, H.J. (1991). The minimumSt Paul, MN). Briefly, 100 ml of supernatants were incubated with
peptide epitope from the influenza virus matrix protein. Extra andanti-IFNg or anti-IL-2 antibody–coated beads. After 2 hr, beads were
intracellular loading of HLA-A2. J. Immunol. 147, 4047–4053.washed and incubated with PE-conjugated anti-IFNg or anti-IL-2
Borriello, F., Oliveros, J., Freeman, G.J., Nadler, L.M., and Sharpe,antibodies. After washing, beads were analyzed by flow cytometry
A.H. (1995). Differential expression of alternate mB7–2 transcripts.(FACScan). The fluorescent signal given by the beads was detected
J. Immunol. 155, 5490–5497.in log scale, and the settings of the PE-channel photomultiplier
(PMT) were adjusted using the blank beads provided in the kit. The Caux, C., Vanbervliet, B., Massacrier, C., Azuma, M., Okumura, K.,
cytokine concentration of the samples was determined by compar- Lanier, L.L., and Banchereau, J. (1994). B70/B7–2 is identical to
ing the mean channel fluorescence of PE obtained with the standard CD86 and is the major functional ligand for CD28 expressed on
curve built by plotting mean channel fluorescence versus cytokine human dendritic cells. J. Exp. Med. 180, 1841–1847.
concentration, for IFNg and IL-2 standards recorded. The IFNg and Chambers, C.A., and Allison, J.P. (1997). Co-stimulation in T cell
IL-2 concentration was given in nanograms per milliliter. responses. Curr. Opin. Immunol. 9, 396–404.
Croft, M. (1994). Activation of naive, memory and effector T cells.
Analysis of Vav Phosphorylation
Curr. Opin. Immunol. 6, 431–437.
Jurkat cells were incubated for 5 min with 5 mg/ml c-myc-tagged
Croft, M., Duncan, D.D., and Swain, S.L. (1992). Response of naiveCD86DTM, anti-CD28, or control mAb. Cross-linking was performed
antigen-specific CD41 T cells in vitro: characteristics and antigen-using an anti-c-myc or goat anti-mouse Ig antibody. Cell lysates
presenting cell requirements. J. Exp. Med. 176, 1431–1437.were incubated with 2 mg anti-Vav polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) adsorbed on protein A-Sepharose Davis, T.A., Craighead, N., Williams, A.J., Scadron, A., June, C.H.,
and Lee, K.P. (1996). Primary porcine endothelial cells express mem-beads. After incubation, beads were washed five times before resus-
pension in loading buffer. Aliquots were subjected to SDS-PAGE brane-bound B7–2 (CD86) and a soluble factor that co-stimulate
Soluble CD86 Is a Costimulatory Molecule
311
cyclosporin A-resistant and CD28-dependent human T cell prolifera- N.R., and Gray, G.S. (1995). Genomic organization of the gene cod-
ing for the costimulatory human B-lymphocyte antigen B7–2 (CD86).tion. Int. Immunol. 8, 1099–1111.
Immunogenetics 42, 85–89.Dong, H., Zhu, G., Tamada, K., and Chen, L. (1999). B7–H1, a third
Keane-Myers, A., Gause, W.C., Linsley, P.S., Chen, S.J., and Wills-member of the B7 family, co-stimulates T cell proliferation and in-
Karp, M. (1997). B7–CD28/CTLA-4 costimulatory pathways are re-terleukin-10 secretion. Nat. Med. 5, 1365–1369.
quired for the development of T helper cell 2-mediated allergic air-
Engel, P., Gribben, J.G., Freeman, G.J., Zhou, L.J., Nozawa, Y., Abe,
way responses to inhaled antigens. J. Immunol. 158, 2042–2049.
M., Nadler, L.M., Wakasa, H., and Tedder, T.F. (1994). The B7–2 (B70)
Klasen, S., Pages, F., Peyron, J.F., Cantrell, D., and Olive, D. (1998).costimulatory molecule expressed by monocytes and activated B
Two distinct regions of the CD28 intracytoplasmic domain are in-lymphocytes is the CD86 differentiation antigen. Blood 84, 1402–
volved in the tyrosine phosphorylation of Vav and GTPase activating1407.
protein-associated p62 protein. Int. Immunol. 10, 481–489.
Fleischer, J., Soeth, E., Reiling, N., Grage-Griebenow, E., Flad, H.D.,
Krummel, M.F., and Allison, J.P. (1995). CD28 and CTLA-4 haveand Ernst, M. (1996). Differential expression and function of CD80
opposing effects on the response of T cells to stimulation. J. Exp.(B7–1) and CD86 (B7–2) on human peripheral blood monocytes.
Med. 182, 459–465.Immunology 89, 592–599.
Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S.,
Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo,
Sobel, R.A., Weiner, H.L., Nabavi, N., and Glimcher, L.H. (1995).
V.A., Lombard, L.A., Gray, G.S., and Nadler, L.M. (1993). Cloning of
B7–1 and B7–2 costimulatory molecules activate differentially the
B7–2: a CTLA-4 counter-receptor that costimulates human T cell
Th1/Th2 developmental pathways: application to autoimmune dis-
proliferation. Science 262, 909–911.
ease therapy. Cell 80, 707–718.
Freeman, G.J., Boussiotis, V.A., Anumanthan, A., Bernstein, G.M., Lalvani, A., Brookes, R., Hambleton, S., Britton, W.J., Hill, A.V., and
Ke, X.Y., Rennert, P.D., Gray, G.S., Gribben, J.G., and Nadler, L.M. McMichael, A.J. (1997). Rapid effector function in CD81 memory T
(1995). B7–1 and B7–2 do not deliver identical costimulatory signals, cells. J. Exp. Med. 186, 859–865.
since B7–2 but not B7–1 preferentially costimulates the initial pro-
Lenschow, D.J., Walunas, T.L., and Bluestone, J.A. (1996). CD28/duction of IL-4. Immunity 2, 523–532.
B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233–258.
Greenfield, E.A., Nguyen, K.A., and Kuchroo, V. (1998). CD28/B7
Linsley, P.S., Clark, E.A., and Ledbetter, J.A. (1990). T cell antigen
costimulation: a review. Crit. Rev. Immunol. 18, 389–418.
CD28 mediates adhesion with B cells by interacting with activation
Gribben, J.G., Freeman, G.J., Boussiotis, V.A., Rennert, P., Jellis, antigen B7/B-1. Proc. Natl. Acad. Sci. USA 87, 5031–5035.
C.L., Greenfield, E., Barber, M., Restivo, V.A., Ke, X., Gray, G.S., and Linsley, P.S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N.K., and
Nadler, L.M. (1995). CTLA-4 mediates antigen-specific apoptosis of Ledbetter, J.A. (1991a). Binding of the B cell activation antigen B7
human T cells. Proc. Natl. Acad. Sci. USA 92, 811–815. to CD28 costimulates T cell proliferation and interleukin 2 mRNA
Guo, Y., Wu, Y., Zhao, M., Kong, X.P., and Liu, Y. (1995). Mutational accumulation. J. Exp. Med. 173, 721–730.
analysis of an alternatively spliced product of B7 defines its CD28/ Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K.,
CTLA4-binding site on immunoglobulin C-like domain. J. Exp. Med. and Ledbetter, J.A. (1991b). CTLA-4 is a second receptor for the B
181, 1345–1355. cell activation antigen B7. J. Exp. Med. 174, 561–569.
Hakamada-Taguchi, R., Kato, T., Ushijima, H., Murakami, M., Uede, Linsley, P.S., Wallace, P.M., Johnson, J., Gibson, M.G., Greene, J.L.,
T., and Nariuchi, H. (1998). Expression and co-stimulatory function Ledbetter, J.A., Singh, C., and Tepper, M.A. (1992). Immunosuppres-
of B7–2 on murine CD41 T cells. Eur. J. Immunol. 28, 865–873. sion in vivo by a soluble form of the CTLA-4 T cell activation mole-
cule. Science 257, 792–795.Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H., and Allison,
J.P. (1992). CD28-mediated signalling co-stimulates murine T cells Linsley, P.S., Nadler, S.G., Bajorath, J., Peach, R., Leung, H.T., Rog-
and prevents induction of anergy in T-cell clones. Nature 356, ers, J., Bradshaw, J., Stebbins, M., Leytze, G., Brady, W., et al.
607–609. (1995). Binding stoichiometry of the cytotoxic T lymphocyte-associ-
ated molecule-4 (CTLA-4). A disulfide-linked homodimer binds twoHathcock, K.S., Laszlo, G., Pucillo, C., Linsley, P., and Hodes, R.J.
CD86 molecules. J. Biol. Chem. 270, 15417–15424.(1994). Comparative analysis of B7–1 and B7–2 costimulatory li-
Liu, Y., and Janeway, C.A. (1992). Cells that present both specificgands: expression and function. J. Exp. Med. 180, 631–640.
ligand and costimulatory activity are the most efficient inducers of
Hutloff, A., Dittrich, A.M., Beier, K.C., Eljaschewitsch, B., Kraft, R.,
clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA
Anagnostopoulos, I., and Kroczek, R.A. (1999). ICOS is an inducible
89, 3845–3849.
T-cell co-stimulator structurally and functionally related to CD28.
Manickasingham, S.P., Anderson, S.M., Burkhart, C., and Wraith,Nature 397, 263–266.
D.C. (1998). Qualitative and quantitative effects of CD28/B7-medi-
Ikemizu, S., Gilbert, R.J., Fennelly, J.A., Collins, A.V., Harlos, K., ated costimulation on naive T cells in vitro. J. Immunol. 161, 3827–
Jones, E.Y., Stuart, D.I., and Davis, S.J. (2000). Structure and dimer- 3835.
ization of a soluble form of B7.1. Immunity 12, 51–60.
Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, P.,
Inobe, M., Linsley, P.S., Ledbetter, J.A., Nagai, Y., Tamakoshi, M., Nadler, L.M., and Griffin, J.D. (1996). B7–1 is superior to B7–2 costim-
and Uede, T. (1994). Identification of an alternatively spliced form ulation in the induction and maintenance of T cell-mediated antileu-
of the murine homologue of B7. Biochem. Biophys. Res. Commun. kemia immunity. Further evidence that B7–1 and B7–2 are function-
200, 443–449. ally distinct. J. Immunol. 156, 1126–1131.
Inobe, M., Aoki, N., Linsley, P.S., Ledbetter, J.A., Abe, R., Murakami, McLellan, A.D., Starling, G.C., Williams, L.A., Hock, B.D., and Hart,
M., and Uede, T. (1996). The role of the B7–1a molecule, an alterna- D.N. (1995). Activation of human peripheral blood dendritic cells
tively spliced form of murine B7–1 (CD80), on T cell activation. J. induces the CD86 co-stimulatory molecule. Eur. J. Immunol. 25,
Immunol. 157, 582–588. 2064–2068.
Mount, S.M. (1982). A catalogue of splice junction sequences. Nu-Jeannin, P., Delneste, Y., Lecoanet-Henchoz, S., Gauchat, J.F., Life,
P., Holmes, D., and Bonnefoy, J.Y. (1995). Thiols decrease human cleic Acids Res. 10, 459–472.
interleukin (IL) 4 production and IL-4-induced immunoglobulin syn- Rennert, P., Furlong, K., Jellis, C., Greenfield, E., Freeman, G.J.,
thesis. J. Exp. Med. 182, 1785–1792. Ueda, Y., Levine, B., June, C.H., and Gray, G.S. (1997). The IgV
domain of human B7–2 (CD86) is sufficient to co-stimulate T lympho-Jeannin, P., Herbault, N., Delneste, Y., Magistrelli, G., Lecoanet-
cytes and induce cytokine secretion. Int. Immunol. 9, 805–813.Henchoz, S., Caron, G., Aubry, J.P., and Bonnefoy, J.Y. (1999). Hu-
man effector memory T cells express CD86: a functional role in Saito, T. (1998). Negative regulation of T cell activation. Curr. Opin.
naive T cell priming. J. Immunol. 162, 2044–2048. Immunol. 10, 313–321.
Shahinian, A., Pfeffer, K., Lee, K.P., Kundig, T.M., Kishihara, K.,Jellis, C.L., Wang, S.S., Rennert, P., Borriello, F., Sharpe, A.H., Green,
Immunity
312
Wakeham, A., Kawai, K., Ohashi, P.S., Thompson, C.B., and Mak,
T.W. (1993). Differential T cell costimulatory requirements in CD28-
deficient mice. Science 261, 609–612.
Swallow, M.M., Wallin, J.J., and Sha, W.C. (1999). B7h, a novel
costimulatory homolog of B7.1 and B7.2, is induced by TNFa. Immu-
nity 11, 423–432.
Symington, F.W., Brady, W., and Linsley, P.S. (1993). Expression
and function of B7 on human epidermal Langerhans cells. J. Immu-
nol. 150, 1286–1295.
Van de Velde, H., Lorre´, K., Bakkus, M., Thielemans, K., Ceuppens,
J.L., and de Boer, M. (1993). CD45RO1 memory T cells but not
CD45RA1 naive T cells can be efficiently activated by remote co-
stimulation with B7. Int. Immunol. 5, 1483–1487.
Vyth-Dreese, F.A., Dellemijn, T.A., Majoor, D., and de Jong, D. (1995).
Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40
and their ligands in normal human lymphoid tissue. Eur. J. Immunol.
25, 3023–3029.
Walker, P.A., Leong, L.E., Ng, P.W., Tan, S.H., Waller, S., Murphy,
D., and Porter, A.G. (1994). Efficient and rapid affinity purification
of proteins using recombinant fusion proteases. Biotechnology 12,
601–605.
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman,
G.J., Green, J.M., Thompson, C.B., and Bluestone, J.A. (1994).
CTLA-4 can function as a negative regulator of T cell activation.
Immunity 1, 405–413.
Yi-qun, Z., Joost van Neerven, R.J., Kasran, A., de Boer, M., and
Ceuppens, J.L. (1996). Differential requirements for co-stimulatory
signals from B7 family members by resting versus recently activated
memory T cells towards soluble recall antigens. Int. Immunol. 8,
37–44.
Yokochi, T., Holly, R.D., and Clark, E.A. (1982). B lymphoblast anti-
gen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts,
B lymphoblastoid cell lines, and Burkitt’s lymphomas. J. Immunol.
128, 823–827.
Yokozeki, H., Katayama, I., Ohki, O., Matsunaga, T., Watanabe, K.,
Satoh, T., Azuma, M., Okumura, K., and Nishioka, K. (1996). Func-
tional CD86 (B7–2/B70) on cultured human Langerhans cells. J.
Invest. Dermatol. 106, 147–153.
Yoshinaga, S.K., Whoriskey, J.S., Khare, S.D., Sarmiento, U., Guo,
J., Horan, T., Shih, G., Zhang, M., Coccia, M.A., Kohno, T., et al.
(1999). T-cell co-stimulation through B7RP-1 and ICOS. Nature 402,
827–832.
Zinkernagel, R.M., Bachmann, M.F., Kundig, T.M., Oehen, S., Pir-
chet, H., and Hengartner, H. (1996). On immunological memory.
Annu. Rev. Immunol. 14, 333–367.
